Compare Recursion Pharmaceuticals Inc (RXRX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Visa Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Visa Inc trades at $369.82 (market cap $691.22B). The key difference: Visa Inc is far larger — about 397.3× Recursion Pharmaceuticals Inc's market cap, and Visa Inc pays a 0.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | V | |
|---|---|---|
Market Cap | $1.74B | $691.22B |
Sector | Health | Financials |
52-Week High | $6.79 | $384.14 |
52-Week Low | $2.84 | $295.52 |
Enterprise Value | $1.26B | $701.80B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Visa (V) trades at $368.64, down 1.71% on the day, but maintains strong fundamentals with a 50.78% net income margin and consistent earnings beats. The stock is supported by a bullish technical signal, with key support at $366 and resistance at $372. Recent developments include the launch of Intelligent Commerce Connect to facilitate AI-driven commerce, positioning the company for future growth amid digital payment expansion.
The outlook for Visa remains positive, driven by robust profitability, strategic AI initiatives, and a consensus price target of $430.93 implying 17% upside. Risks include competitive pressures from fintech and stablecoins, as well as regulatory scrutiny. Wall Street sentiment is overwhelmingly bullish with 85% of analysts rating it a Buy, supported by institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
